Related Experiment Video

Updated: May 14, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate

Kennosuke Karube1, Shinobu Tsuzuki, Noriaki Yoshida

  • 1Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan.

Cancer Letters
|January 26, 2013
PubMed

Insights

This study identifies the JAK-STAT pathway activation in Natural Killer (NK) cell neoplasms. Vorinostat effectively suppressed NK cell proliferation, suggesting its potential as a targeted therapy for these aggressive lymphoid malignancies.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Natural Killer (NK) cell neoplasms are aggressive lymphoid malignancies.
  • Understanding the molecular pathways driving NK cell neoplasms is crucial for developing effective treatments.

Purpose of the Study:

  • To analyze gene expression profiles of NK cell neoplasms.
  • To identify key molecular pathways and potential therapeutic drugs.
  • To investigate the role of JAK-STAT pathway activation.

Main Methods:

  • Gene expression profiling and pathway analysis (JAK-STAT, NF-κB, Wnt).
  • Western blot analysis to assess protein expression and phosphorylation (STAT3).
  • Connectivity Map (CMAP) analysis for drug candidate identification.
  • In vitro drug screening using NK cell lines and other cell lines.

Main Results:

  • Pathway analysis implicated JAK-STAT, NF-κB, and Wnt pathways in NK cell neoplasms.
  • Elevated STAT3 expression and phosphorylation confirmed JAK-STAT pathway activation.
  • Vorinostat demonstrated significant suppression of NK cell line proliferation at low concentrations.
  • Vorinostat's efficacy was linked to the suppression of the JAK-STAT pathway.

Conclusions:

  • JAK-STAT pathway activation is a key feature of NK cell neoplasms.
  • Vorinostat shows promise as a therapeutic agent for NK cell neoplasms.
  • Targeting the JAK-STAT pathway with drugs like vorinostat may offer a new treatment strategy.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...